A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Recruiting

Phase 1

A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid TumorsA Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Sponsor:

Cullinan Therapeutics Inc.

Code:

NCT05117476

Conditions

Advanced Solid Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

CLN-619

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-24. This information was provided to ClinicalTrials.gov by Cullinan Therapeutics Inc. on 2025-02-03.